Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India

J Postgrad Med. 2013 Jul-Sep;59(3):226-8. doi: 10.4103/0022-3859.118046.

Abstract

We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Amphotericin B / therapeutic use
  • Antiprotozoal Agents / therapeutic use
  • Disease Reservoirs
  • Female
  • Humans
  • India
  • Leishmania donovani
  • Leishmaniasis, Cutaneous / drug therapy
  • Leishmaniasis, Cutaneous / parasitology*
  • Leishmaniasis, Visceral / complications*
  • Leishmaniasis, Visceral / drug therapy
  • Leishmaniasis, Visceral / parasitology
  • Male

Substances

  • Antiprotozoal Agents
  • liposomal amphotericin B
  • Amphotericin B